pirfenidone has been researched along with Rheumatoid Arthritis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Adamali, HI; Chambers, DC; Chaudhuri, N; Cox, PG; Danoff, SK; Dellaripa, PF; Flaherty, KR; Forrest, IA; Gibbons, MA; Glaspole, I; Goldberg, HJ; Golden, J; Gooptu, B; Hurwitz, S; Kolb, M; Lasky, JA; Lynch, DA; Maurer, R; Perrella, MA; Raghu, G; Rosas, IO; Scholand, MB; Solomon, JJ; Spencer, LG; Spino, C; Troy, L; Vassallo, R; Woodhead, FA | 1 |
| Graudal, N; Lindhardsen, J; Nielsen, CT | 1 |
| Hurwitz, S; Maurer, R; Rosas, IO; Solomon, JJ | 1 |
| Distler, J; Fischer, A | 1 |
| Chambers, DC; Danoff, SK; Dellaripa, PF; DiFranco, D; Goldberg, HJ; Haynes-Harp, S; Hurwitz, S; Kolb, M; Peters, EB; Rosas, IO; Solomon, JJ; Spino, C; Woodhead, F | 1 |
| Lin, H; Wu, C; Zhang, X | 1 |
| Giri, SN; Margolin, SB; Pesce, E; Struma, E | 1 |
1 review(s) available for pirfenidone and Rheumatoid Arthritis
| Article | Year |
|---|---|
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Indoles; Kaplan-Meier Estimate; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Risk Factors; Tomography, X-Ray Computed | 2019 |
3 trial(s) available for pirfenidone and Rheumatoid Arthritis
| Article | Year |
|---|---|
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Topics: Adult; Arthritis, Rheumatoid; COVID-19; Double-Blind Method; Humans; Lung Diseases, Interstitial; Pandemics; Treatment Outcome | 2023 |
The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Longitudinal Studies; Lung Diseases, Interstitial; Male; Middle Aged; Pyridones; Risk Factors; United States | 2019 |
Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chi-Square Distribution; Double-Blind Method; Female; Humans; Male; Middle Aged; Oxyphenbutazone; Patient Dropouts; Pilot Projects; Pyridones; Treatment Outcome | 2004 |
3 other study(ies) available for pirfenidone and Rheumatoid Arthritis
| Article | Year |
|---|---|
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease.
Topics: Arthritis, Rheumatoid; Humans; Lung; Lung Diseases, Interstitial; Pyridones | 2023 |
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease - Authors' reply.
Topics: Arthritis, Rheumatoid; Humans; Lung Diseases, Interstitial; Pyridones | 2023 |
Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
Topics: Activating Transcription Factor 3; Adult; Aged; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cell Differentiation; Cell Movement; Cells, Cultured; Disease Models, Animal; Down-Regulation; Female; Fibroblasts; Gene Knockdown Techniques; Humans; Lung; Lung Diseases, Interstitial; Male; Mice, Inbred C57BL; Middle Aged; Myofibroblasts; Pulmonary Fibrosis; Pyridones | 2019 |